Nxera Pharma Co., Ltd. (4565.T)
JPY 1056.0
(1.15%)
JPY 1056.0
(1.15%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.19 Billion JPY | -1982.98% |
| 2022 | 382 Million JPY | -62.44% |
| 2021 | 1.01 Billion JPY | -31.24% |
| 2020 | 1.47 Billion JPY | 3.28% |
| 2019 | 1.43 Billion JPY | 118.02% |
| 2018 | -7.94 Billion JPY | -199.45% |
| 2017 | -2.65 Billion JPY | -127.54% |
| 2016 | 9.63 Billion JPY | 723.01% |
| 2015 | -1.54 Billion JPY | -375.01% |
| 2014 | 562.52 Million JPY | -63.14% |
| 2013 | 1.52 Billion JPY | 335.94% |
| 2012 | -646.85 Million JPY | 66.9% |
| 2011 | -1.95 Billion JPY | -4.41% |
| 2010 | -1.87 Billion JPY | -5.81% |
| 2009 | -1.76 Billion JPY | 55.08% |
| 2008 | -3.93 Billion JPY | 39.44% |
| 2007 | -6.5 Billion JPY | -4.23% |
| 2006 | -6.23 Billion JPY | -49.42% |
| 2005 | -4.17 Billion JPY | -129.39% |
| 2004 | -1.82 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.42 Billion JPY | 56.66% |
| 2024 Q3 | 1.2 Billion JPY | 184.39% |
| 2024 Q1 | -3.28 Billion JPY | -1477.4% |
| 2023 Q2 | -658 Million JPY | 53.07% |
| 2023 FY | -7.19 Billion JPY | -1982.98% |
| 2023 Q3 | -4.92 Billion JPY | -648.48% |
| 2023 Q1 | -1.4 Billion JPY | -138.87% |
| 2023 Q4 | -208 Million JPY | 95.78% |
| 2022 FY | 382 Million JPY | -62.44% |
| 2022 Q4 | 3.6 Billion JPY | 1052.4% |
| 2022 Q3 | 313 Million JPY | 121.32% |
| 2022 Q2 | -1.46 Billion JPY | 29.08% |
| 2022 Q1 | -2.07 Billion JPY | -172.84% |
| 2021 FY | 1.01 Billion JPY | -31.24% |
| 2021 Q4 | 2.84 Billion JPY | 502.12% |
| 2021 Q3 | 472 Million JPY | 141.26% |
| 2021 Q1 | -1.15 Billion JPY | -136.94% |
| 2021 Q2 | -1.14 Billion JPY | 0.78% |
| 2020 FY | 1.47 Billion JPY | 3.28% |
| 2020 Q1 | -746 Million JPY | -2472.41% |
| 2020 Q2 | -1.37 Billion JPY | -83.78% |
| 2020 Q3 | 475 Million JPY | 134.65% |
| 2020 Q4 | 3.12 Billion JPY | 557.05% |
| 2019 Q2 | -622 Million JPY | -161.1% |
| 2019 Q1 | 1.01 Billion JPY | 138.42% |
| 2019 FY | 1.43 Billion JPY | 118.02% |
| 2019 Q3 | 1.06 Billion JPY | 271.38% |
| 2019 Q4 | -29 Million JPY | -102.72% |
| 2018 Q3 | -2.07 Billion JPY | -32.08% |
| 2018 FY | -7.94 Billion JPY | -199.45% |
| 2018 Q2 | -1.56 Billion JPY | -66.63% |
| 2018 Q1 | -941 Million JPY | 22.55% |
| 2018 Q4 | -2.65 Billion JPY | -27.96% |
| 2017 Q1 | -976 Million JPY | -4747.62% |
| 2017 FY | -2.65 Billion JPY | -127.54% |
| 2017 Q4 | -1.21 Billion JPY | -45.16% |
| 2017 Q3 | -837 Million JPY | -387.63% |
| 2017 Q2 | 291 Million JPY | 129.82% |
| 2016 FY | 9.63 Billion JPY | 723.01% |
| 2016 Q3 | -504 Million JPY | -104.54% |
| 2016 Q4 | 21 Million JPY | 104.17% |
| 2016 Q2 | 11.09 Billion JPY | 394.82% |
| 2016 Q1 | -3.76 Billion JPY | -215.25% |
| 2015 FY | -1.54 Billion JPY | -375.01% |
| 2015 Q1 | 300.3 Million JPY | 28.89% |
| 2015 Q2 | -811 Million JPY | -370.06% |
| 2015 Q3 | -30 Million JPY | 96.3% |
| 2015 Q4 | 3.26 Billion JPY | 10986.67% |
| 2014 Q4 | 233 Million JPY | 76.52% |
| 2014 Q1 | 1.92 Billion JPY | 630.01% |
| 2014 FY | 562.52 Million JPY | -63.14% |
| 2014 Q2 | -104.02 Million JPY | -105.39% |
| 2014 Q3 | 132 Million JPY | 226.9% |
| 2013 Q4 | -364.07 Million JPY | -163.96% |
| 2013 FY | 1.52 Billion JPY | 335.94% |
| 2013 Q2 | -608.66 Million JPY | -36.4% |
| 2013 Q1 | -446.22 Million JPY | -1977.39% |
| 2013 Q3 | 569.26 Million JPY | 193.53% |
| 2012 Q1 | -586.6 Million JPY | 4.16% |
| 2012 FY | -646.85 Million JPY | 66.9% |
| 2012 Q2 | -653.85 Million JPY | -11.46% |
| 2012 Q4 | -21.48 Million JPY | -104.52% |
| 2012 Q3 | 474.7 Million JPY | 172.6% |
| 2011 Q4 | -612.04 Million JPY | -173.17% |
| 2011 Q3 | -224.05 Million JPY | 57.86% |
| 2011 Q2 | -531.68 Million JPY | 20.18% |
| 2011 Q1 | -666.14 Million JPY | -13.11% |
| 2011 FY | -1.95 Billion JPY | -4.41% |
| 2010 Q1 | -743.4 Million JPY | -39.55% |
| 2010 Q2 | 10.47 Million JPY | 101.41% |
| 2010 Q3 | -627.27 Million JPY | -6086.02% |
| 2010 FY | -1.87 Billion JPY | -5.81% |
| 2010 Q4 | -588.94 Million JPY | 6.11% |
| 2009 Q2 | 276.09 Million JPY | 168.38% |
| 2009 Q3 | -769.13 Million JPY | -378.57% |
| 2009 Q4 | -532.72 Million JPY | 30.74% |
| 2009 FY | -1.76 Billion JPY | 55.08% |
| 2009 Q1 | -403.73 Million JPY | 76.15% |
| 2008 Q4 | -1.69 Billion JPY | -84.69% |
| 2008 FY | -3.93 Billion JPY | 39.44% |
| 2008 Q3 | -916.65 Million JPY | 0.0% |
| 2007 FY | -6.5 Billion JPY | -4.23% |
| 2006 FY | -6.23 Billion JPY | -49.42% |
| 2005 FY | -4.17 Billion JPY | -129.39% |
| 2004 FY | -1.82 Billion JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 1973.177% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | -1265.118% |
| GNI Group Ltd. | 8.09 Billion JPY | 188.866% |
| Linical Co., Ltd. | 338.26 Million JPY | 2226.433% |
| Trans Genic Inc. | 4.08 Million JPY | 176183.231% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | -400.226% |
| Soiken Holdings Inc. | -662.2 Million JPY | -986.223% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | 5306.471% |
| AnGes, Inc. | -7.43 Billion JPY | 3.289% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | -458.403% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | 3952.829% |
| NanoCarrier Co., Ltd. | -780 Million JPY | -822.177% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | -523.908% |
| CanBas Co., Ltd. | -1.2 Billion JPY | -494.955% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | -785.389% |
| RaQualia Pharma Inc. | -323.66 Million JPY | -2122.38% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | -489.581% |
| Kidswell Bio Corporation | -1.42 Billion JPY | -405.809% |
| PeptiDream Inc. | 3.03 Billion JPY | 336.937% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | -271.059% |
| Ribomic Inc. | -1.02 Billion JPY | -602.279% |
| SanBio Company Limited | -2.64 Billion JPY | -172.05% |
| Healios K.K. | -3.82 Billion JPY | -88.151% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | -515.796% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | -382.881% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | -403.221% |
| StemRIM | -2.02 Billion JPY | -255.737% |
| CellSource Co., Ltd. | 923.14 Million JPY | 879.187% |
| FunPep Company Limited | -933.41 Million JPY | -670.61% |
| Kringle Pharma, Inc. | -854.15 Million JPY | -742.123% |
| Stella Pharma Corporation | -763.74 Million JPY | -841.802% |
| TMS Co., Ltd. | -960.04 Million JPY | -649.24% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | -536.541% |
| Cuorips Inc. | -632.18 Million JPY | -1037.803% |
| K Pharma,Inc. | 260.33 Million JPY | 2863.032% |
| Takara Bio Inc. | 1.48 Billion JPY | 586.014% |
| ReproCELL Incorporated | -31.41 Million JPY | -22796.705% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | 27368.936% |
| StemCell Institute Inc. | 310.98 Million JPY | 2413.003% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | 5124.132% |
| CellSeed Inc. | -846.53 Million JPY | -749.7% |